ArmaGen Technologies Obtains $17,000,000 Series A Funding Round

  • Feed Type
  • Date
    12/3/2012
  • Company Name
    ArmaGen Technologies
  • Mailing Address
    914 Colorado Ave Santa Monica, CA 90401
  • Company Description
    ArmaGen provides platform technology solutions to the ‘blood-brain barrier’ problem, and can non-invasively target recombinant proteins, therapeutic monoclonal antibodies, and siRNA to the brain.
  • Website
    http://www.armagen.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $17,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The company will use the financing to start clinical trials of its biopharmaceutical candidates.
  • M&A Terms
  • Venture Investor
    Shire Pharmaceuticals
  • Venture Investor
    Takeda Ventures
  • Venture Investor
    Mitsui & Co.
  • Venture Investor
    Boehringer Ingelheim Venture Fund

By posting a comment, you agree to our terms and conditions.